These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35200549)

  • 1. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
    Prete AA; Procaccio L; Bergamo F; Rasola C; Nappo F; Zagonel V; Lonardi S
    Curr Oncol; 2022 Jan; 29(2):544-550. PubMed ID: 35200549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?
    Garajová I; Balsano R; Gelsomino F; Leonardi F
    Tumori; 2022 Dec; 108(6):NP30-NP33. PubMed ID: 36299234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
    Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
    Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Li M; Mou Y; Hou S; Cao D; Li A
    Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
    Wang D; Guan R; Tao Q; Liu S; Yu M; Li X
    BMC Med Genomics; 2021 Jan; 14(1):6. PubMed ID: 33407459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
    Wu C; Fan M; Hu Y
    Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
    PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
    Assaf I; Mans L; Sakr R; Verset G; Van Laethem JL
    Eur J Cancer; 2021 Nov; 157():63-67. PubMed ID: 34487986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
    Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.